Document Detail

Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL.
MedLine Citation:
PMID:  16271314     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Seasonal affective disorder (SAD) can cause significant distress and impairment. No antidepressant studies have previously attempted to prevent the onset of autumn-winter depression. METHODS: Three prospective, randomized, placebo-controlled prevention trials were conducted on 1042 SAD patients, enrolled in autumn and treated while still well, across the northern US and Canada. Patients received either bupropion XL 150-300 mg or placebo daily by mouth from enrollment until spring and were then followed off medications for 8 additional weeks. Primary efficacy variables were end-of-treatment depression-free rates and survival distributions of depressive recurrence. RESULTS: Despite a reported average of 13 previous seasonal depressive episodes, almost 60% of patients had never previously been treated for depression. Major depression recurrence rates during the three studies for bupropion XL and placebo groups were 19% versus 30% (p = 0.026), 13% versus 21% (p = 0.049), and 16% versus 31%; yielding a relative risk reduction across the three studies of 44% for patients taking bupropion XL. Survival analyses for depression onset also favored bupropion XL over placebo (p = .081, .057, and <.001). CONCLUSIONS: It is possible to prevent recurrence of seasonal major depressive episodes by beginning bupropion treatment early in the season while patients are still well.
Jack G Modell; Norman E Rosenthal; April E Harriett; Alok Krishen; Afsaneh Asgharian; Vicki J Foster; Alan Metz; Carol B Rockett; Donna S Wightman
Related Documents :
21721994 - Comparison of post-treatment effects of conventional and acupuncture-like transcutaneou...
7857504 - Hypericum in the treatment of seasonal affective disorders.
8882914 - Sunny hospital rooms expedite recovery from severe and refractory depressions.
2236584 - Treatment of winter depression with a portable, head-mounted phototherapy device.
7775644 - Inhibition of steroid 5 alpha-reductase with finasteride: sleep-related erections, pote...
24136634 - Effectiveness of telemonitoring integrated into existing clinical services on hospital ...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Biological psychiatry     Volume:  58     ISSN:  0006-3223     ISO Abbreviation:  Biol. Psychiatry     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-11-07     Completed Date:  2006-02-07     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0213264     Medline TA:  Biol Psychiatry     Country:  United States    
Other Details:
Languages:  eng     Pagination:  658-67     Citation Subset:  IM    
GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antidepressive Agents, Second-Generation / therapeutic use*
Body Weight / drug effects
Bupropion / therapeutic use*
Double-Blind Method
Drug Administration Schedule
Follow-Up Studies
Middle Aged
Prospective Studies
Psychiatric Status Rating Scales
Recurrence / prevention & control
Retrospective Studies
Seasonal Affective Disorder / prevention & control*
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Antidepressive Agents, Second-Generation; 34841-39-9/Bupropion

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Psychological and cognitive effects of long-term peyote use among Native Americans.
Next Document:  Pediatric rhegmatogenous retinal detachment in East Asians.